Successful Treatment With Tofacitinib for Renal Disorder due to Amyloid A Amyloidosis and Immunoglobulin A Nephropathy in a Patient With Rheumatoid Arthritis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Scientific Articles

Successful Treatment With Tofacitinib for Renal Disorder due to Amyloid A Amyloidosis and Immunoglobulin A Nephropathy in a Patient With Rheumatoid Arthritis

key information

source: Clinical and Experimental Rheumatology

year: 2018

authors: Watanabe T, Hattori T, Ogawa Y, Jodo S

summary/abstract:

Amyloid A (AA) amyloidosis is a rare but serious complication of chronic inflammatory diseases like rheumatoid arthritis (RA), causing progressive organ dysfunction in the kidneys, neurons, or gastrointestinal tract. Tofacitinib is an oral, small-molecule Janus kinase (JAK) inhibitor, used for the treatment of moderate and severe RA (2, 3). Here, we report a case of a 76-year-old woman with RA who developed renal disorder due to AA amyloidosis and immunoglobulin A nephropathy (IgAN). Tofacitinib therapy improved her kidney involvement. This patient developed RA at the age of 60. Anti-tumour necrosis factor α (anti-TNF-α) agents, infliximab and golimumab, tocilizumab (TCZ), and abatacept (ABA) were administered, in that order, to treat her active RA.

In December 2014, the patient, who was receiving ABA, was admitted to our department due to worsening kidney function. Signs of declining kidney function included a serum creatinine (s-Cr) level of 1.18 mg/dL (normal, 0.41-0.75), a proteinuria of 2.60 g/day (normal, <0.15), and over 100 red blood cells (RBCs) per high power field (/HPF) (normal, <5) with granular and erythrocytic casts.

organization: Tomakomai City Hospital, Japan; Hokkaido Renal Pathology Center, Japan

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2024 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close